{
    "clinical_study": {
        "@rank": "16641", 
        "arm_group": {
            "arm_group_label": "Gemcitabine, Carboplatin, and Panitumumab (GCaP)", 
            "arm_group_type": "Experimental", 
            "description": "Patients will receive four cycles of GCaP administered every 21 days. Panitumumab will be administered intravenously at a dose of 9mg/kg on day 1. Gemcitabine 1,000 mg/m2 on day 1 and 8 and carboplatin AUC 4.5 on day 1 will be administered intravenously on a 21-day cycle. A total of four cycles of therapy will be administered at 21-day intervals followed by radical cystectomy."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to find out if using the combination of standard chemotherapy\n      (gemcitabine and carboplatin) plus this new drug (panitumumab) can help to shrink the tumor\n      before the patient undergoes surgery for bladder cancer."
        }, 
        "brief_title": "Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer", 
        "condition": "Bladder Cancer", 
        "condition_browse": {
            "mesh_term": "Urinary Bladder Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed muscle invasive transitional cell carcinoma of the bladder\n             at MSKCC (Note: urothelial carcinoma invading into the prostatic stroma with no\n             histologic muscle invasion is allowed, provided the extent of disease is confirmed\n             via imaging and/or EUA.)\n\n          -  Clinical stage T2-T4a N0/X M0 disease.\n\n          -  Medically appropriate candidate for radical cystectomy as per MSKCC attending\n             urologic oncologist\n\n          -  Karnofsky Performance Status \u2265 80%\n\n          -  Age \u2265 18 years of age\n\n          -  Required Initial Laboratory Values:\n\n        Absolute neutrophil count \u2265 1500 cells/mm3\n\n          -  Platelets \u2265 100,000 cells/mm3\n\n          -  Hemoglobin \u2265 9.0g/dL\n\n          -  Bilirubin \u2264 1.5 the upper limit of normal (ULN) for the institution\n\n          -  Aspartate transaminase (AST) and alanine transaminase (ALT) \u2264 2.5 x ULN for the\n             institution\n\n          -  Alkaline phosphatase \u2264 2.5 x ULN for the institution\n\n          -  Serum magnesium > 1.4 mEq/L\n\n          -  Serum creatinine \u2264 2.0 mg/dL\n\n          -  Cisplatin ineligibility based on one or more of the following criteria:\n\n        Estimated glomerular filtration rate (eGFR) 30-59 ml/min/1.73m2 using the CKD-EPI\n        equation:(http://nephron.org/MDRD_GFR.cgi) :\n\n        eGFR = 141 x min(Scr/k, 1)a x max(Scr/k, 1)-1.209 x 0.993Age x 1.018 [if female] x 1.159\n        [if black] Scr is serum creatinine, k is 0.7 for females and 0.9 for males, a is -0.329\n        for females and -0.411 for males, min indicates the minimum of Scr/k or 1, and max\n        indicates the maximum of Scr/k or 1.\n\n          -  Grade 2 sensory neuropathy\n\n          -  Grade 2 hearing loss\n\n               -  Patients must provide a pretreatment saliva sample for genomic analysis.\n\n        Exclusion Criteria:\n\n          -  Prior systemic chemotherapy (prior intravesical therapy is allowed)\n\n          -  Serious intercurrent medical or psychiatric illness.\n\n          -  Prior radiation therapy to the bladder.\n\n          -  Concomitant use of any other investigational drugs\n\n          -  Any of the following within the 6 months prior to study drug administration:\n             myocardial infarction, grade 2 or greater peripheral vascular disease, arterial\n             thrombotic event, visceral arterial ischemia, cerebrovascular ischemia, transient\n             ischemic attack, percutaneous transluminal angioplasty or stent, or unstable angina.\n\n        Symptomatic and/or serious uncontrolled arrhythmia\n\n          -  Symptomatic congestive heart failure (NYHA class III or IVI)\n\n          -  History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or\n             evidence of interstitial lung disease on baseline chest CT scan.\n\n          -  History of any medical or psychiatric condition or laboratory abnormality that in the\n             opinion of the investigator may increase the risk associated with the study\n             participation or investigational product(s) administration or may interfere with the\n             interpretation of the results.\n\n          -  Major surgery requiring general anesthesia within 21 days or minor surgery within 14\n             days of study enrollment. Subjects must have recovered from surgery related\n             toxicities.\n\n          -  Pulmonary embolism, deep vein thrombosis, or other significant venous event \u2264 8 weeks\n             before enrollment\n\n          -  Known allergy or hypersensitivity to any component of the study treatment(s)\n\n          -  Active infection requiring systemic treatment or any uncontrolled infections \u226414 days\n             prior to enrollment.\n\n          -  Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome\n             (AIDS)-related illness.\n\n          -  Concurrent treatment on another clinical trial. Supportive care trials,  surgical\n             clinical trials or non-treatment trials, e.g. QOL, are allowed.\n\n          -  Ongoing treatment with therapeutic doses of warfarin (low dose warfarin up to 2 mg po\n             daily for thromboembolic prophylaxis is allowed).\n\n          -  Pregnancy or breast-feeding. Patients must be surgically sterile or be\n             postmenopausal, or must agree to use effective contraception during the period of\n             therapy and for two (2) months following the last dose of panitumumab. The definition\n             of effective contraception will be based on the judgment of the principal\n             investigator or a designated associate. Male patients must be surgically sterile or\n             agree to use effective contraception."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01916109", 
            "org_study_id": "10-103"
        }, 
        "intervention": [
            {
                "arm_group_label": "Gemcitabine, Carboplatin, and Panitumumab (GCaP)", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Gemcitabine, Carboplatin, and Panitumumab (GCaP)", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Gemcitabine, Carboplatin, and Panitumumab (GCaP)", 
                "intervention_name": "Panitumumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Gemcitabine, Carboplatin, and Panitumumab (GCaP)", 
                "intervention_name": "radical cystectomy", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Carboplatin", 
                "Antibodies, Monoclonal"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Gemcitabine", 
            "Carboplatin", 
            "Panitumumab", 
            "(GCaP)", 
            "radical cystectomy", 
            "10-103"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "link": {
            "description": "Memorial Sloan-Kettering Cancer Center", 
            "url": "http://www.mskcc.org/"
        }, 
        "location": [
            {
                "contact": {
                    "last_name": "Dean Bajorin, MD", 
                    "phone": "646-422-4333"
                }, 
                "facility": {
                    "address": {
                        "city": "Basking Ridge", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }, 
                    "name": "Memoral Sloan Kettering Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Dean Bajorin, MD", 
                    "phone": "646-422-4333"
                }, 
                "facility": {
                    "address": {
                        "city": "Commack", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11725"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center @ Suffolk"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Dean Bajorin, MD", 
                    "phone": "646-422-4333"
                }, 
                "contact_backup": {
                    "last_name": "Jonathan Rosenberg, MD", 
                    "phone": "646-422-4461"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Dean Bajorin, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Dean Bajorin, MD", 
                    "phone": "646-422-4333"
                }, 
                "facility": {
                    "address": {
                        "city": "Rockville Centre", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Memorial Sloan-Kettering at Mercy Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Dean Bajorin, MD", 
                    "phone": "646-422-4333"
                }, 
                "facility": {
                    "address": {
                        "city": "Sleepy Hollow", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Memoral Sloan Kettering Cancer Center@Phelps"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer", 
        "overall_contact": {
            "last_name": "Dean Bajorin, MD", 
            "phone": "646-422-4333"
        }, 
        "overall_contact_backup": {
            "last_name": "Jonathan Rosenberg, MD", 
            "phone": "646-422-4461"
        }, 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Dean Bajorin, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "defined as the absence of carcinoma (pT0 disease) and the absence of microscopic lymph node metastases (N0) on the final cystectomy specimen.", 
                "measure": "pathologic complete response rate (<pT0)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "The frequency and severity of toxicities will be tabulated according to the NCI common toxicity criteria version 4.0.", 
                "measure": "safety", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01916109"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "defined as the absence of muscle invasive carcinoma (<pT2 disease) and the absence of microscopic lymph node metastases (N0) on the final cystectomy specimen.", 
                "measure": "pathologic response rate (<pT2)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Time to progression is measured from the time of initiation of chemotherapy until the first date that systemic recurrence is objectively documented. Systemic recurrence for this trial is defined as either metastatic or local pelvic recurrence.", 
                "measure": "disease progression", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "overall survival will be estimated using the methods of Kaplan and Meier.", 
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}